March 17 (Reuters) - Lantheus Holdings ( LNTH ) said on
Tuesday that the U.S. Food and Drug Administration has extended
its review of the company's diagnostic imaging kit by three
months.
The agency will now give its decision on the imaging kit's
approval by June 29.